NVO•benzinga•
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
Summary
Certain genes may predict strong responses to Novo Nordisk's Wegovy (semaglutide) in obesity treatment, with patients showing significant weight loss linked to a "hungry gut" genetic profile. This finding could enhance personalized obesity care, optimizing treatment outcomes.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2024 by benzinga